INFORMATION FOR
News
The Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center provides coordinated, state-of-the-art care for patients with benign and malignant diseases of the breast.
The Breast Cancer Specialty Team at Smilow Cancer Hospital in Guilford brings together clinicians whose focus is caring for patients with breast cancer on the Connecticut Shoreline.
Results from two WHRY studies were recently published in peer-reviewed journals.
For the past 25 years, Women's Health Research at Yale has been investigating conditions of high morbidity and mortality in women and understanding sex and gender differences that affect health outcomes.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
A diverse team of BRCA gene experts work together to unlock the secrets of DNA repair and develop better breast, ovarian and other cancer treatments.
Smilow Cancer Hospital Care Centers in Fairfield and Trumbull will be hosting a virtual Smilow Shares program on “Breast Cancer Awareness and Treatment Advances” on Tuesday, October 21 at 7pm.
Smilow Cancer Hospital Care Centers in Waterford and Westerly will be hosting a virtual Smilow Shares program on “Breast Cancer Awareness and Treatment Advances” on Tuesday, October 28 at 7pm.
Across the country, it’s becoming clearer every day: We must study the health of women. We must study the influence of sex-and-gender differences on health. And it’s time for all aspects of medical research and practice to embrace this change.
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Yale Cancer Center is proud to announce the Basser BRCA Initiative grant. The $1 million, three-year gift was awarded to YCC by the Gray Foundation to advance the next generation of cancer therapies.
Women’s Health Research at Yale (WHRY) is funding a study to explain how well-known genetic mutations can lead to ovarian cancer.
The BRCA1 gene and its association with breast cancer were discovered in 1990.
A proposal for improving the partnership between metastatic breast cancer patients and their medical care teams has garnered Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven a $358,000 award from the National Comprehensive Cancer Network (NCCN) in collaboration with Pfizer. Only ten awards were given to cancer centers around the country.
Yale University researchers have discovered why a key molecular assistant is crucial to the function of the BRCA2 gene, which in some mutant forms can lead to ovarian and breast cancer in as many as 6 in 10 women. The findings suggest how biochemists might be able to decrease drug resistance to existing therapies that target this form of cancer, the authors report in the July 2 issue of the journal Molecular Cell.
The DNA in the nuclei of our cells gets tattered every day from forces within, such as free radical damage, and also from without, such as the sun’s UV rays
In a healthcare climate where the costs of treatment are increasingly weighed against potential benefit, a Yale study has found that radiation oncologists are using fewer or less-aggressive radiation procedures on elderly women with early-stage breast cancer.
Spreading awareness about male breast cancer has become a calling for Catherine Szerszen and her fiancé Bob Havens ever since Bob was diagnosed with stage I breast cancer in 2023.
In an interview, Rachel Perry, PhD, discusses the link between insulin and cancer, a surprising finding in her research, and the future of precision medicine for metabolism-related cancers.